Atrius India Core FHIR Implementation Guide
0.1.0 - ci-build

Atrius India Core FHIR Implementation Guide - Local Development build (v0.1.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

: Atrius Drug-Drug Interaction Check

Draft as of 2026-08-30

Raw json | Download

{
  "resourceType" : "PlanDefinition",
  "id" : "atrius-ddi-check",
  "meta" : {
    "profile" : [
      🔗 "http://hl7.org/fhir/StructureDefinition/cdshooksserviceplandefinition|4.0.1"
    ]
  },
  "language" : "en",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>See <code>Library/AtriusDrugInteractions</code> for pair definitions and drug-class ValueSets.</p></div>"
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/cqf-cdsHooksEndpoint",
      "valueUri" : "https://cds.atrius.in/cds-services/atrius-ddi-check"
    }
  ],
  "url" : "https://atrius.in/fhir/r4/atrius-in/PlanDefinition/atrius-ddi-check",
  "identifier" : [
    {
      "use" : "official",
      "value" : "atrius-ddi-check"
    },
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:1.3.6.1.4.1.66219.1.34.2"
    }
  ],
  "version" : "0.1.0",
  "name" : "AtriusDdiCheck",
  "title" : "Drug-Drug Interaction Check",
  "type" : {
    "coding" : [
      {
        "system" : "http://terminology.hl7.org/CodeSystem/plan-definition-type",
        "code" : "eca-rule"
      }
    ]
  },
  "status" : "draft",
  "experimental" : true,
  "date" : "2026-08-30T18:15:29+05:30",
  "publisher" : "Atrius",
  "contact" : [
    {
      "name" : "Atrius",
      "telecom" : [
        {
          "system" : "url",
          "value" : "https://atrius.in"
        }
      ]
    }
  ],
  "description" : "Interruptive alerts at order signing when a draft medication order interacts with an active prescription: statin + CYP3A4-inhibiting macrolide (rhabdomyolysis), warfarin + NSAID (bleeding), ACE inhibitor + potassium-sparing diuretic (hyperkalemia). Cards propose safer alternatives or monitoring.",
  "library" : [
    🔗 "https://atrius.in/fhir/r4/atrius-in/Library/AtriusDrugInteractions|0.1.0"
  ],
  "action" : [
    {
      "id" : "atrius-ddi-check-root",
      "title" : "Drug-Drug Interaction Check",
      "description" : "A draft order interacts with an active prescription.",
      "trigger" : [
        {
          "type" : "named-event",
          "name" : "order-sign"
        }
      ],
      "condition" : [
        {
          "kind" : "applicability",
          "expression" : {
            "language" : "text/cql",
            "expression" : "Has Drug Interaction"
          }
        }
      ],
      "input" : [
        {
          "type" : "Patient",
          "profile" : [
            🔗 "https://atrius.in/fhir/r4/atrius-in/StructureDefinition/atrius-in-patient|0.1.0"
          ]
        },
        {
          "type" : "MedicationRequest",
          "profile" : [
            🔗 "https://atrius.in/fhir/r4/atrius-in/StructureDefinition/atrius-in-medicationrequest|0.1.0"
          ]
        }
      ],
      "groupingBehavior" : "logical-group",
      "action" : [
        {
          "id" : "ddi-statin-macrolide",
          "title" : "Statin + macrolide: rhabdomyolysis risk",
          "description" : "Clarithromycin and erythromycin inhibit CYP3A4 and raise statin exposure, risking myopathy and rhabdomyolysis. Consider azithromycin (minimal CYP3A4 inhibition) or hold the statin for the antibiotic course.",
          "priority" : "stat",
          "documentation" : [
            {
              "type" : "documentation",
              "display" : "AHA statement — statin drug interactions",
              "url" : "https://www.ahajournals.org/doi/10.1161/CIR.0000000000000456",
              "document" : {
                "url" : "https://www.ahajournals.org/doi/10.1161/CIR.0000000000000456"
              }
            }
          ],
          "condition" : [
            {
              "kind" : "applicability",
              "expression" : {
                "language" : "text/cql",
                "expression" : "Statin Macrolide Interaction"
              }
            }
          ],
          "groupingBehavior" : "logical-group",
          "selectionBehavior" : "at-most-one",
          "action" : [
            {
              "id" : "ddi-statin-macrolide-azithromycin",
              "title" : "Switch to azithromycin (no CYP3A4 interaction)",
              "priority" : "stat",
              "definitionCanonical" : "https://atrius.in/fhir/r4/atrius-in/ActivityDefinition/atrius-ad-med-azithromycin|0.1.0"
            }
          ]
        },
        {
          "id" : "ddi-warfarin-nsaid",
          "title" : "Warfarin + NSAID: bleeding risk",
          "description" : "NSAIDs potentiate warfarin and independently injure gastric mucosa, sharply raising GI bleeding risk. Prefer paracetamol for analgesia; if an NSAID is unavoidable, add gastroprotection and increase INR monitoring.",
          "priority" : "stat",
          "documentation" : [
            {
              "type" : "documentation",
              "display" : "Warfarin drug interactions (StatPearls)",
              "url" : "https://www.ncbi.nlm.nih.gov/books/NBK470313/",
              "document" : {
                "url" : "https://www.ncbi.nlm.nih.gov/books/NBK470313/"
              }
            }
          ],
          "condition" : [
            {
              "kind" : "applicability",
              "expression" : {
                "language" : "text/cql",
                "expression" : "Warfarin NSAID Interaction"
              }
            }
          ],
          "groupingBehavior" : "logical-group",
          "selectionBehavior" : "at-most-one",
          "action" : [
            {
              "id" : "ddi-warfarin-nsaid-paracetamol",
              "title" : "Use paracetamol for analgesia instead",
              "priority" : "stat",
              "definitionCanonical" : "https://atrius.in/fhir/r4/atrius-in/ActivityDefinition/atrius-ad-med-paracetamol|0.1.0"
            }
          ]
        },
        {
          "id" : "ddi-acei-k-sparing",
          "title" : "ACE inhibitor + potassium-sparing diuretic: hyperkalemia risk",
          "description" : "Combined ACE inhibitor and potassium-sparing diuretic therapy risks hyperkalemia, particularly with renal impairment. If co-prescription is intended, check baseline and follow-up potassium and renal function.",
          "priority" : "urgent",
          "documentation" : [
            {
              "type" : "documentation",
              "display" : "UK Kidney Association — acute hyperkalaemia guideline",
              "url" : "https://ukkidney.org/health-professionals/guidelines/treatment-acute-hyperkalaemia-adults",
              "document" : {
                "url" : "https://ukkidney.org/health-professionals/guidelines/treatment-acute-hyperkalaemia-adults"
              }
            }
          ],
          "condition" : [
            {
              "kind" : "applicability",
              "expression" : {
                "language" : "text/cql",
                "expression" : "ACE Inhibitor Potassium Sparing Diuretic Interaction"
              }
            }
          ],
          "groupingBehavior" : "logical-group",
          "action" : [
            {
              "id" : "ddi-acei-k-sparing-bmp",
              "title" : "Order potassium and renal function (BMP)",
              "priority" : "urgent",
              "definitionCanonical" : "https://atrius.in/fhir/r4/atrius-in/ActivityDefinition/atrius-ad-lab-bmp|0.1.0"
            }
          ]
        }
      ]
    }
  ]
}